Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 789 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA-mutated Metastatic... August 25, 2023 Sugar and cancer – what you need to know October 20, 2020 ESMO Asia Congress 2023, 1-3 December 2023, Singapore November 24, 2023 Coping With Cancer Recurrence: My Perspective As Both a Patient and... January 24, 2023 Load more HOT NEWS Mohs Surgery for Skin Cancer: What to Know and What to... Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent... New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers Antioxidant Use Before And During Chemo Increases Risk Of Relapse, Death...
